ArticleArthritis research & therapy2022

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.

M Verstappen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.